Apis Capital Advisors’s MaxCyte MXCT Stock Holding History

Apis Capital Advisors’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-45,800	Closed	-$192K	–	40
2024 Q1	$192K	Buy	+45,800	New	+$215K	0.15%	36
2022 Q4	–	Sell	-200,000	Closed	-$1.3M	–	29
2022 Q3	$1.3M	Buy	200,000 +6,271	+3%	+$35K	1.95%	15
2022 Q2	$916K	Buy	193,729 +13,729	+8%	+$67.6K	1.03%	23
2022 Q1	$1.26M	Sell	180,000 -40,000	-18%	-$273K	1.52%	22
2021 Q4	$2.24M	Sell	220,000 -152,000	-41%	-$1.63M	2.48%	17
2021 Q3	$4.54M	Buy	+372,000	New	+$5.61M	4.33%	9

Other funds holding MXCT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Mudita Advisors London, United Kingdom $490M AUM 66.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Apis Capital Advisors's MXCT Position: Q2 2024 in Review

Apis Capital Advisors sold out of MaxCyte (MXCT) in Q2 2024, closing a stake of 45,800 shares — an estimated $192K sold.

Apis Capital Advisors first reported a position in MXCT in Q3 2021 and held it in 6 quarters. The position peaked at $4.54M in Q3 2021. 114 funds tracked by Wall St. Rank hold MXCT as of Q2 2024.

Apis Capital Advisors reported no remaining MaxCyte position as of Q2 2024 after selling out during the quarter.
Apis Capital Advisors sold 45,800 MaxCyte shares in Q2 2024, an estimated $192K.
Apis Capital Advisors first reported a position in MaxCyte in Q3 2021 and held it in 6 quarters.
Apis Capital Advisors's MaxCyte position peaked at $4.54M in Q3 2021.
114 funds tracked by Wall St. Rank held MaxCyte as of Q2 2024.

Based on Apis Capital Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.